Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
HUMANIGEN, INC (HGEN)
Sector: Healthcare; Industry: Biotechnology

Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase I/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-01-20 NOMIS BAY LTD. 10%-Owner Sell 8,500 $20.29 $172,423 No
2021-01-19 NOMIS BAY LTD. 10%-Owner Sell 105,000 $18.94 $1,989,020 No
2021-01-12 NOMIS BAY LTD. 10%-Owner Sell 25,000 $18.67 $466,650 No
2020-12-28 NOMIS BAY LTD. 10%-Owner Sell 500 $22.20 $11,101 No
2020-12-22 NOMIS BAY LTD. 10%-Owner Sell 50,000 $20.02 $1,000,985 No
2020-12-24 NOMIS BAY LTD. 10%-Owner Sell 53,401 $21.24 $1,134,104 No
2020-12-22 NOMIS BAY LTD. 10%-Owner Sell 50,000 $50000.00 $2,500,000,000 No
2020-12-21 NOMIS BAY LTD. 10%-Owner Sell 87,700 $16.82 $1,474,766 Yes
2020-08-10 NOMIS BAY LTD. 10%-Owner Sell 17,100 $5.04 $86,098 No
2020-07-28 NOMIS BAY LTD. 10%-Owner Sell 10,000 $5.66 $56,550 No
2020-07-20 NOMIS BAY LTD. 10%-Owner Sell 300,000 $5.00 $1,500,190 No
2020-06-30 NOMIS BAY LTD. 10%-Owner Sell 3,000 $4.91 $14,739 No
2020-06-16 NOMIS BAY LTD. 10%-Owner Sell 65,000 $5.63 $365,798 No
2020-06-10 NOMIS BAY LTD. 10%-Owner Sell 516,260 $2.62 $1,353,281 No
2018-02-27 NOMIS BAY LTD. 10%-Owner Buy 29,893,424 $0.28 $8,370,159 No
2018-02-27 Chappell Dale 10%-Owner Buy 32,028,669 $0.09 $3,001,086 No
2017-08-30 NOMIS BAY LTD. 10%-Owner Sell 38,900 $0.46 $17,894 No
2016-08-26 Shkreli Martin 10%-Owner Sell 2,222,929 $3.10 $6,891,080 No
2015-12-16 Anthion Partners II LLC 10%-Owner Buy 6,820 $29.32 $199,962 No
2015-12-16 Fernandez Thomas Edward Director Buy 6,821 $29.32 $199,992 No
2015-12-16 BIESTEK MAREK Director Buy 10,000 $29.32 $293,200 No
2015-12-16 Harrison Michael Wayne Director Buy 1,705 $29.32 $49,991 No
2015-12-16 Anthion Partners II LLC 10%-Owner Buy 6,820 $29.32 $199,962 No
2015-11-24 Shkreli Martin Chief Executive Officer Buy 5,000 $38.15 $190,750 No
2015-11-20 Shkreli Martin Chief Executive Officer Buy 5,000 $18.88 $94,400 No
2015-11-18 Anthion Partners II LLC 10%-Owner Buy 300,000 $2.13 $639,000 No
2015-11-18 BIESTEK MAREK nan Buy 40,000 $2.04 $81,600 No
2015-11-18 Shkreli Martin 10%-Owner Buy 440,000 $2.02 $888,800 No
2015-11-17 BIESTEK MAREK nan Buy 200,000 $1.68 $335,450 No
2015-11-17 Anthion Partners II LLC 10%-Owner Buy 713,726 $1.42 $1,014,263 No

Insider Smart

Axsome Therapeutics, Inc (AXSM) - AXSM shows the power of an #allgreen stock, no insider selling, great management great company, if you follow the insiders last year and pick up around $25, the 52 week high is $100+.

Insider Smart

VBI Vaccines Inc (VBIV) - Since 10%-owner Perceptive Advisor LCC increased their holding in April, the stock have double the price. Impressive!